SINOVAC科兴新冠疫苗克尔来福^®在特殊人群中的应用研究概览

截至2022年3月底，由科兴控股生物技术有限公司（下称“SINOVAC科兴”）研制的克尔来福^®已在61个国家/地区/国际组织获批，在56个国家和地区使用，并在全球范围内针对适种人群展开了诸多临床及真实世界研究。同时，克尔来福^®在特殊健康状况人群中也积累了大量的应用经验，显示出良好的安全性、免疫原性及有效性。

克尔来福^®安全性良好

优于巴西同期使用的另3款新冠疫苗

恶性实体瘤患者接种克尔来福^Ⓡ后

不良反应发生率略低于健康人群

HIV感染者接种克尔来福^Ⓡ后

不良事件发生率与健康人群相当

参考文献

[1] Balcells, M. Elvira, et al. "Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile." Clinical Infectious Diseases (2022). https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac167/6543937?login=true

[2] Netto, Lucas C., et al. "Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study." The Lancet HIV (2022). https://www.sciencedirect.com/science/article/pii/S2352301822000339

[3] Esquivel-Valerio, Jorge Antonio, et al. "Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study." Rheumatology international 41.12 (2021): 2105-2108. https://link.springer.com/article/10.1007/s00296-021-05017-9

[4] Yuki, Emily FN, et al. "Impact of distinct therapies on antibody response to SARS‐CoV‐2 vaccine in systemic lupus erythematosus." Arthritis care & research (2021). https://onlinelibrary.wiley.com/doi/full/10.1002/acr.24824 

[5] Ciampi, Ethel, et al. "Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis." Multiple Sclerosis and Related Disorders 59 (2022): 103690. https://doi.org/10.1016/j.msard.2022.103690

[6] Pasoto, Sandra Gofinet, et al. "Inactivated SARS-CoV-2 vaccine in primary Sjögren’s syndrome: humoral response, safety, and effects on disease activity."  Clinical Rheumatology  (2022): 1-11. https://link.springer.com/article/10.1007/s10067-022-06134-x

[7] Xiong, Xi, et al. "Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study." Thyroid ja (2022).https://www.liebertpub.com/doi/abs/10.1089/thy.2021.0684

[8] Palacios, Ricardo, et al. "Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study." (2021). https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780

[9] Zhang, Yuemiao, et al. "Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients." medRxiv (2022). https://doi.org/10.1101/2022.01.14.22269182

[10] Medina-Pestana, José, et al. "Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in kidney transplant recipients." Transplantation 106.1 (2022). https://journals.lww.com/transplantjournal/Fulltext/2022/01000/Clinical_Impact,_Reactogenicity,_and.40.aspx

[11] Medina-Pestana, José, et al. "Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study." Clinical Kidney Journal 14.12 (2021): 2612-2615. https://academic.oup.com/ckj/article/14/12/2612/6353597?login=false

[12] Yasin, Ayse Irem, et al. "Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study." Future Oncology 0 (2022). https://www.futuremedicine.com/doi/full/10.2217/fon-2021-1248

[13] Paixao, Enny S., et al. "CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study." BMC medicine 20.1 (2022): 1-8. https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02353-w

[14] Qiao, Yaping, et al. "Safety profile of COVID-19 vaccines in pregnant and postpartum women in brazil." medRxiv (2021). https://www.medrxiv.org/content/10.1101/2021.12.14.21267777v1

[15] https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1